Abstract: The invention discloses a pretreatment method, a preservation method, an automatic treatment system and a detection method for a urine sample, and directs to the technical field of biological detection. The pretreatment method comprises subjecting a urine sample after protein lysis to a reductive alkylation treatment, followed by protein enrichment and enzymolysis. The protein enrichment is performed on the sample after the reductive alkylation treatment using a PVDF filter plate for protein enrichment; The invention also provides an automatic treatment system and an automatic sample treatment method. The treatment system greatly reduces the labor intensity of people, is beneficial to facilitate the treatment efficiency of urine sample treatment, meets the requirements of high-flux and automated pretreatment of the proteomics, and accommodates the reproducibility and flux of current clinical needs.

Abstract: A polymer hydrogel with a slow-release function, and a preparation method and use thereof are provided. The polymer hydrogel includes the following components in mass percentage contents: 0.01% to 15% of an active ingredient, 0.01% to 15% of an ion inhibitor, 0.01% to 1% of a crosslinking agent, 0.1% to 10% of a polymer resin, 10% to 35% of a solvent, 0.1% to 15% of a skin-touch regulator, 10% to 55% of deionized water, 0.1% to 3% of an appearance modifier, 0.01% to 1% of a crosslinking regulator, 0.01% to 1% of a preservative, and 0.01% to 5% of a transdermal absorption enhancer. The polymer hydrogel prepared by the present disclosure has excellent skin adaptability and skin permeability, long drug slow-release time, and excellent bioadhesion to the skin, and can be repeatedly peeled off without residue.

Abstract: The present disclosure provides a marker and use thereof in predicting a possibility of a subject with diabetes. The marker described may include at least one of ?-hydroxybutyric acid (?-HB), 1,5-anhydroglucitol (1,5-AG), asymmetric dimethylarginine (ADMA), cystine, ethanolamine, taurine, L-leucine, L-tryptophan, hydroxylysine, and L-aspartate. The possibility of the subject with diabetes may be predicted using a prediction model (e.g., prediction models 2-5) related to the marker based on a concentration of the marker. The prediction model 2 is related to ?-HB. The prediction model 3 is related to 1,5-AG and ADMA. The prediction model 4 is related to cystine, ethanolamine, taurine, L-leucine, L-tryptophan and hydroxylysine. The prediction model 5 is related to ?-HB, 1,5-AG, cystine, ethanolamine, taurine and L-aspartate.

Abstract: The embodiments of the present disclosure provide a method for analyzing a body fluid proteome. The method comprises: obtaining a sample to be tested I enriched with low-abundance proteins by removing high-abundance proteins in an initial sample A using an affinity technique; obtaining a sample to be tested II enriched with low-abundance proteins by removing high-abundance proteins in an initial sample B using chemical precipitation, wherein the initial sample A and the initial sample B are obtained from a same body fluid sample of a same subject; obtaining a proteome data set I by performing proteomic analysis on the sample to be tested I; obtaining a proteome data set II by performing proteomic analysis on the sample to be tested II; and determining a final quantified proteome data set of the body fluid sample based on the proteome data set I and the proteome data set II.

Abstract: The present disclosure provides a marker and use thereof in predicting a possibility of a subject with diabetes. The marker described may include at least one of ?-hydroxybutyric acid (?-HB), 1,5-anhydroglucitol (1,5-AG), asymmetric dimethylarginine (ADMA), cystine, ethanolamine, taurine, L-leucine, L-tryptophan, hydroxylysine, and L-aspartate. The possibility of the subject with diabetes may be predicted using a prediction model (e.g., prediction models 2-5) related to the marker based on a concentration of the marker. The prediction model 2 is related to ?-HB. The prediction model 3 is related to 1,5-AG and ADMA. The prediction model 4 is related to cystine, ethanolamine, taurine, L-leucine, L-tryptophan and hydroxylysine. The prediction model 5 is related to ?-HB, 1,5-AG, cystine, ethanolamine, taurine and L-aspartate.

Abstract: Polymers, hydrogels, and thermochromic agents, including products embodying them, methods of using them, and processes for making them. In certain embodiments, temperature therapy packs which utilize thermochromic agents integrated into solid, semi-solid, or liquid hydrogels. In preferred (but optional) embodiments, the thermochromic agents are integrated into the composition used as the temperature exchange material of the therapy pack. In certain other embodiments, methods of using the thermochromic integrated temperature exchange materials, or processes for manufacturing such thermochromic integrated temperature exchange materials and/or methods or processes for manufacturing or using thermal packs embodying such materials. In certain particularly preferred embodiments, novel polymer compositions and/or processes for making polymers, which improve product durability or longevity and/or which improve use cycles or usage times.

Abstract: An apparatus for positioning an introducer sheath includes a sheath having a distal end including first and second ports, the second port being located distally from the first port. An obturator is slidable within the sheath that includes a distal region that sealingly engages an interior surface of the sheath. The obturator includes first and second openings in the distal region that are alignable with the first and second ports in the sheath. A housing is slidable on the exterior of the sheath that releasably holds a closure element. The sheath may be inserted into an incision communicating with a blood vessel, the first and second ports providing backbleed indication of the depth of the insertion of the sheath into the vessel. The housing is actuated to deploy the closure element to engage and close the incision.

Abstract: A safety syringe has a retaining device formed on a front end of the barrel, multiple bosses formed on the needle hub to rotatably correspond to the retaining device, multiple recesses defined inside the needle hub and multiple inclined teeth formed on the plunger to correspond to the recesses, such that the engagement between the retaining device and the bosses of the needle hub is able to be released by the rotational movement of the plunger together with the needle hub due to the combination of the inclined teeth and the recesses.

Abstract: An apparatus for delivering a closure element into a puncture communicating with a blood vessel includes an introducer sheath, and a locator member disposed within the sheath, the locator member having a distal portion extending distally beyond the distal end of the sheath. A plurality of splines are provided on the distal portion of the locator member, the splines being selectively expandable between an axial collapsed configuration and a transverse expanded configuration. An actuator is coupled to the locator member for controllably expanding the splines. A housing is slidably disposed on the sheath for deploying a closure element, such as a vascular clip. The locator actuator may automatically collapse the splines upon advancement of the housing.

Abstract: Apparatus and methods are provided for use in sealing a vascular puncture site. The invention comprises an introducer sheath with an integrated closure component. The closure component includes an advanceable resilient spring clip with an expanded delivery configuration in which opposing sides do not contact one another, and an unstressed deployed configuration, in which opposing sides close towards one another. The clip is advanced along the sheath until it pierces opposing sides of a vessel wall at a puncture site. The sheath then is withdrawn, thereby causing the clip to resiliently return to its unstressed deployed configuration and draw opposing sides of the puncture together to seal the wound.

Abstract: Apparatus and methods are provided for use in sealing a vascular puncture site. The invention comprises an introducer sheath with an integrated closure component. The closure component includes an advanceable resilient spring clip with an expanded delivery configuration in which opposing sides do not contact one another, and an unstressed deployed configuration, in which opposing sides close towards one another. The clip is advanced along the sheath until it pierces opposing sides of a vessel wall at a puncture site. The sheath then is withdrawn, thereby causing the clip to resiliently return to its unstressed deployed configuration and draw opposing sides of the puncture together to seal the wound.